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Introduction 
 
Since the vast majority of people suffering from tuberculosis (TB) come from the poorer 
and most vulnerable segments of society, global TB control targets cannot be met unless this 
group of people is reached with essential health services.  Early diagnosis and effective treatment 
are important aspects that help reduce the adverse social and financial consequences of the 
disease for TB patients and their families.  Consequently, all influential policy documents on TB 
control always highlight the importance of developing strategies that ensure global access to 
essential health services for all TB patients.  
Despite the successes achieved by the adoption of the Directly Observed Therapy, short 
course (DOTS) strategy in countries such as Peru, the recent emergence of multidrug resistant 
(MDR) TB and extremely drug resistant (XDR) TB has slowed down the progress toward the 
ultimate goal of TB control and elimination. Originally named after one of the components of the 
strategy, DOTS comprises four other critical components including: government commitment, 
case detection by sputum smear microscopy, uninterrupted drug supply and standardized 
reporting and recording.   Given this new understanding, a fast, simple and cost-effective tool to 
assess anti-TB treatment efficacy becomes a paramount aspect of this goal.   
The thesis is organized in the following sections. The background section provides an 
overview of tuberculosis and the problem of multidrug resistant tuberculosis around the world. 
These sections are followed by a review of the current state of TB in Peru and MDR TB as the 
new threat facing the Peruvian national TB program.  Following the background, the author 
presents an original prospective cohort study on the correlation of cough frequency and treatment 
efficacy of pulmonary TB patients in Lima, Peru.  The main objective of this study was to test 
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the hypothesis that cough frequency will decrease in patients receiving effective treatment for 
susceptible TB strains.  This was done through a survey administered to pulmonary TB patients 
during their treatment.  The purpose of undertaking this study was to explore the use of cough 
frequency as a clinical marker for treatment efficacy.  Understanding this correlation promises to 
deliver an inexpensive and reliable method of determining treatment efficacy, especially in the 
era of MDR TB and XDR TB. 
Tuberculosis 
 Current State of Tuberculosis 
 
The Mycobacterium tuberculosis complex includes five species: M. tuberculosis, M. 
bovis, M. canetti, M. africanum, and M. microti.  Most human disease is caused by M. 
tuberculosis.  These bacilli, transmitted on airborne droplets, can cause a lung disease that if left 
untreated will kill about 50% of patients.1  About 9 million people around the world developed 
tuberculosis (TB) for the first time in 2010, and nearly 2 million people died with or from the 
disease.  Globally, TB is currently responsible for more years of healthy life lost (2.5 percent of 
all disability-adjusted life years, or DALYs) than any other infectious disease, bar AIDS and 
malaria.2 Only AIDS is responsible for more deaths.  Ninety five percent of cases and deaths 
occur in developing countries and TB accounts for approximately seven percent of all deaths in 
developing countries.3   
The total cost of the global TB epidemic can be difficult to grasp. Often the local health 
services and families are responsible for the direct monetary costs associated with the diagnosis 
and treatment of the disease.  In addition, the loss of income and decreased production when 
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those afflicted by the disease—often the most productive members of society— are too sick to 
work or die prematurely are indirect costs borne by the local communities.   
Finally, one should not forget that like many other diseases, tuberculosis also carries with 
it enormous psychological and social costs that cannot be properly quantified in DALYs or 
dollars but are nonetheless very real to those who suffer from the disease. 
Further exacerbating the global TB problem is the continuing emergence of multidrug-
resistant (MDR) TB.  MDR-TB is resistant to treatment with isoniazid and rifampin—the two 
most potent first-line TB drugs.  Diagnosis and treatment of MDR-TB in endemic areas is a 
relatively new public health challenge. Successful response requires isolation of infectious 
patients, rapid procurement of and treatment with second-line medications, and consistent 
directly observed therapy (DOT). On a global scale, many rural communities do not have 
adequate resources or the expertise needed to address this daunting public health problem.  
Higher morbidity and mortality rates occur with MDR-TB than with drug susceptible TB.4 
MDR-TB is a growing challenge to all regions of the world. TB control programs that are 
not achieving basic standards can create MDR-TB cases because of inadequate DOT. These 
same programs will likely have a difficult time managing the costs of treating MDR-TB cases. 
Small TB programs may struggle to manage outbreaks in a timely manner.  Avoidable delays in 
diagnosis can result in the surprisingly rapid expansion of infectious cases and contacts with 
latent MDR-TB disease, which can cause the potential for MDR-TB to be firmly entrenched in 
the community for many years. 
In the United States, from the 1950s until the mid 1980s, there was approximately a 5% 
annual decline in the case rate of TB.  From 1985 to the early 1990s, however, the incidence of 
the disease increased by 20%.4  This increase primarily affected young, urban, racial and ethnic 
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minority populations.  Tuberculosis was more prevalent among the homeless, illicit drug users 
and inmates of correctional facilities.5  Another important trend during this time period centered 
on an increase in the number of immigrants to the United States from countries with high 
prevalence of TB.  In two decades, the percentage of TB cases in the United States attributed to 
foreign-born persons had increased from 22% in 1985 to 58% in 2007.1    
 After 1992, the increasing incidence of TB in the United States stabilized and then began 
to decline once again.  By 2010, the case reports of TB had declined by over 50% reaching 
11,181 cases (or 3.6 cases per 100,000).6  Despite the advances in the control and elimination of 
this disease, TB rates among Hispanics, blacks, and Asians were seven, eight, and 25 times 
greater, respectively, than among whites.  The TB case rate in 2010 for foreign-born persons was 
11 times greater than the rate for US-born persons.  Unfortunately, the target of TB elimination 
was not reached by 2010, a goal established in 1989.  Moreover, the decrease in overall case 
rates has slowed in recent years from 7.8% during the 1990s to 3.8% over the past few years.6 
 Microbiology of Tuberculosis 
 
Unlike other bacteria, mycobacteria are acid and alcohol fast.  This means that if stained 
by an aniline dye, such as carbolfuchsin, their thick, lipid-rich wall resists decolorization when 
they come into contact with acid and alcohol.  This unique property of mycobacteria has led to 
the medical community to refer to them as "acid-fast bacilli" (AFB) and highlights the 
importance of mycobacteria’s wall to their survival.7  On the other hand,  this property also 
allows for the detection of AFB in sputum specimens.  This is often done by the simple Ziehl-
Neelsen (ZN) staining technique, widely used throughout the world.7  This is an inexpensive tool 
that can be carried out rapidly.  
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Mycobacteria are slow growers.  Each generation time is often measured in hours rather 
than minutes.  Consequently, the normal methods of obtaining cultures from clinical specimens 
are difficult because of overgrowth by other bacteria.  Fortunately, the thick cell wall of 
mycobacteria also enables them to resist alkalis and detergents, which are used to reduce 
contamination during culture.7 
 Transmission and Risk of Infection 
 
People infected with M. tuberculosis carry live tubercle bacilli, usually in their lungs.  
However, the bacilli may be present in small numbers and dormant or latent.  In this case, there 
may be no apparent disease and the person is termed to have a latent TB infection (LTBI) 
Disease occurs when the bacteria overcome the body’s immune defenses, and become numerous 
enough to cause damage to tissues.8  Patients with pulmonary TB are the most important source 
of infection.  Infection generally occurs by inhaling droplet nuclei.  These nuclei contain tubercle 
bacilli in infectious particles usually less than 5 micrometers in size.8  These are spread into the 
air by coughing, sneezing, talking, spitting, or singing, and they can remain suspended in the air 
for long periods of time, especially in dark, unventilated environments.8  For example, a single 
cough can produce 3,000 infectious droplet nuclei.  Droplet nuclei are so small that they pass 
undetected through most defenses and penetrate into the terminal alveoli of the lungs, where 
multiplication and infection begins.8 
The probability of transmission of the disease is determined by several different factors:  
1) the infectiousness of the source case (that is, how many tubercle bacilli are being coughed into 
the air); 2) The immune status of the host and the susceptibility to contacts;  3) The duration of 
exposure and closeness of contact;  4) The environment in which the exposure takes place, 
especially small, poorly ventilated places.7  Patients with positive sputum smear for acid-fast 
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bacilli or with cavities on chest radiograph (CXR) are much more infectious than those with 
negative sputum smears or without cavities on CXR.7  Following infection, the tubercle bacilli 
are ingested by alveolar macrophages in the lungs.  It is here that they multiply slowly with 
bacterial cell division occurring every 25 to 32 hours.  This facilitates their spread to the local 
lymph nodes, and then to the rest of the body.8   Approximately two to eight weeks after this 
primary infection, most infected humans develop an immune response to the tubercle bacilli 
called delayed-type hypersensitivity.  Unless there is a defect in the cell-mediated immune 
response, it stops further multiplication of the bacteria, and the only evidence of infection is a 
positive response to an immunological test, most commonly the tuberculin skin test.9  
If disease develops, infiltrates and lesions usually appear within the lung tissue.8  The 
immune response of the patient results in a pathological lesion, which is characteristically 
localized, often with extensive tissue destruction and cavitation.10  These cavitating lesions often 
contain many actively dividing bacilli.10 Sputum from patients with these lesions is usually 
smear-positive.10 
The proportion of any population infected depends on the rate and duration of exposure, 
which can vary from one group of people to another.  There are, however, some common 
patterns.  Infection rates are always observed to increase monotonically with age.11  This is 
partially explained by the ability of this infection to remain dormant for many years.  Although 
the infection rates in boys and girls are usually indistinguishable, adult men appear to suffer from 
higher infection rates than adult women.  This discrepancy is most likely not related to the 
intrinsic susceptibility of men to the infection.  In general, men probably suffer more from TB 
than women because they are more exposed to infection.12,13 
9 
 
The size of the infecting dose of tubercle bacilli and the immune status of the host 
determine the risk of progression from infection to disease.  The estimated lifetime risk of 
disease for a newly infected person is 10%, with approximately half of that risk occurring in the 
first two years after infection.14  This development is most common in children under five years 
of age and adults with advanced immunosuppression.14  Infants and young children up to the age 
of five years who are infected with M. tuberculosis appear to be at relatively high risk, 
particularly of severe forms (mainly miliary TB and TB meningitis), because of their immature 
immune systems.  The risk is also high during adolescence and remains stable during adulthood.  
The elderly, especially over the age of 65, also suffer from higher risk.15 
Other factors that enhance the risk of developing TB following infection include under-
nutrition, toxins (tobacco, alcohol, corticosteroids, immunosuppressive drugs), and other diseases 
(diabetes mellitus, silicosis, leukemia, measles, and whooping cough in children).  However, the 
most important risk factor remains HIV co-infection.16 
 Clinical Manifestations 
 
Clinical diagnoses of tuberculosis distinguish between pulmonary and extrapulmonary 
disease, the former being of much greater importance epidemiologically. 
 Pulmonary Tuberculosis 
 
Patients with pulmonary TB present with a chronic productive cough, fever, and weight 
loss.8  Cough occurs in a variety of circumstances, notably in acute upper and lower respiratory 
infections.   However, these acute infections often resolve within three weeks.  Thus, a patient 
with a cough longer than three weeks, especially after a course of antibiotics, should be 
investigated for pulmonary TB.17 
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The diagnosis of pulmonary TB in most hospitals in countries with limited resources is 
based on sputum smear microscopy and chest radiography.  Most countries have a reference 
laboratory where M. tuberculosis can be cultured from clinical specimens, such as sputum.  
Because M. tuberculosis is a slow-growing organism taking two to three months to become 
visible on culture medium, cultures are not usually helpful in making an individual diagnosis.  
Mycobacterial cultures are commonly used for monitoring drug-sensitivity patterns in patients 
with recurrent TB and for monitoring the community prevalence of drug-resistant TB.18 
Taking sputum specimens (three per suspect) for smear microscopy of AFB is a cheap and 
simple way to screen for pulmonary TB.19  If sputum smear examination is negative, patients 
suspected of having pulmonary TB should have a chest radiography.19  Chest radiography 
suggestive of disease usually show upper lobe disease, bilateral disease, and cavitations.  These 
findings are more common in HIV-negative patients than HIV-positive patients.  However, no 
pattern is absolutely diagnostic of TB.10 
 Extrapulmonary Tuberculosis 
 
 Extrapulmonary TB accounts for 20% of all cases of TB in HIV-seronegative patients.  
This percentage increases to approximately 50% in HIV co-infection.20  Among HIV-
seronegative patients extrapulmonary TB is most common in females and young patients.20  The 
common signs or forms of extrapulmonary TB include pleural effusion, lymphadenopathy, 
pericardial effusion, miliary disease, and meningitis.  Patients usually present with constitutional 
symptoms and local features related to the site of disease.  If patients cough for longer than three 
weeks, sputum smear examination and chest radiography are often carried out, because of the 
likely possibility of coexisting pulmonary disease.  Definitive diagnosis of extrapulmonary TB 
depends on having diagnostic tools, such as radiographs, ultrasound scans, procedures to obtain 
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and analyze fluid samples, and procedures for tissue biopsies and histological analysis.20 This 
degree of diagnostic sophistication is often unavailable in many areas of the world.  For example, 
in one study in Tanzania only 18 percent of patients diagnosed with extrapulmonary TB had 
laboratory confirmation of the diagnosis.21 
 Childhood Tuberculosis 
 
 Approximately 11% of all cases of TB occur in children (classified as patients under the 
age of 15).  Children are most commonly infected with M. tuberculosis as a result of 
transmission from an adult in their close environment (usually the household) with smear-
positive disease.  Most children remain asymptomatic, and a positive tuberculin test may be the 
only evidence of infection.  For those who progress to disease, pulmonary TB is the most 
common manifestation in both children with and without HIV-coinfection.  Extrapulmonary 
disease, however, is more frequent in those who are HIV positive and meningitis appears to be 
the most common manifestation in very young children (age less than 3).  Although more 
common in children than adults, the patterns of extrapulmonary TB in children and the 
diagnostic problems encountered are similar to those described for adults.22 
The diagnosis of childhood pulmonary TB has always been difficult because of the lack 
of sputum production and the paucity or absence of tubercle bacilli in respiratory secretions, 
since they typically remain confined to perihilar nodes that do not rupture into the bronchus.23  A 
presumptive diagnosis, therefore, usually relies on a combination of clinical features, history of 
contact with a sputum-positive case, CXR and tuberculin skin test.17  Unfortunately, CXR 
findings and clinical features are often nonspecific.  M. tuberculosis recovery from gastric 
aspiration, induced sputum, and nasopharyngeal aspiration show promise as alternative 
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diagnostic techniques but are not practical under routine clinical conditions in limited resource 
settings.23 
 Multi-Drug Resistant Tuberculosis 
 Introduction 
 
 Multidrug-resistant (MDR) tuberculosis (TB) is defined as TB caused by Mycobacterium 
tuberculosis strains resistant to at least the two “first-line” anti-TB medications, isoniazid and 
rifampin.  MDR TB is a growing global health threat.  The World Health Organization (WHO) 
estimates that about 500,000 cases of MDR TB occur annually, or 5.4% of the 9.3 million cases 
of TB that occur worldwide.24,25  The treatment required for this form of the disease consists of 
combination therapy with four to six drugs for a period of time averaging two years.18  These 
“second line” agents are significantly more toxic, less potent and more costly.  Consequently, 
MDR TB has lower cure rates, higher mortality and a much higher cost for a single treatment 
course.18,26,27  Even in settings with optimal public health program resources, including directly 
observed therapy and intensive case management, overall cure rates are lower, ranging from 65 
to 75%.28,29   
Given the complexities of the disease, MDR TB requires a high level of laboratory 
capacity for accurate and effective diagnosis as well as fairly intensive management.  
Unfortunately, there has been very little progress in the area of diagnostic and treatment services 
needed to handle the current, estimated annual case burden.  As of late 2010, the Stop TB 
Partnership Working Group for MDR TB reports that since 2000 approximately 100,000 MDR 
TB patients have been treated or are currently undergoing treatment in appropriate program 
conditions approved by the group’s Green Light Committee quality assurance mechanism.30  
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This represents less than 10% of all the MDR TB cases that have occurred around the globe 
during the same time period.  Further evidence of the need to improve diagnostic and treatment 
capacity for MDR TB around the world is the very high mortality rate for the disease.  Currently, 
~ 150,000 or 30% of the annual MDR TB incident cases in the world die of the disease.  Even if 
patients are able to enter good treatment programs, mortality ranges from 8 to 21%.27,28,29 
 Risk Factors for MDR TB 
 
 Understanding the risk factors for MDR TB can help clinicians and public health officials 
identify potential cases early.  Early detection might facilitate rapid diagnosis, initiation of 
appropriate treatment sooner and use of enhanced infection control measures to reduce the 
transmission of MDR TB strains.   
Human Immunodeficiency Virus (HIV) infection is among the strongest risk factors for 
progression from TB infection to active TB disease.  The risk for progression is over 20 times 
higher for those patients co-infected with TB and HIV compared with those without HIV 
infection.31  In a prospective study of 169 patients by Vernon et al, HIV positive patients under 
treatment for TB had a greater risk of developing rifabutin resistance during the course of TB 
treatment.32  Indeed, a direct association between HIV infection and TB drug resistance has been 
suggested by a number of reports.18,33   
In addition to HIV infection, there are several risk factors that increase the likelihood that 
a given patient who presents with TB has MDR TB.  These factors include a history of previous 
treatment for TB, especially if this treatment course failed, and having contact with a known case 
of MDR TB.18 
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 Diagnosis 
 
 In settings where resources and health infrastructure are limited, TB is diagnosed based 
on the results of sputum smear staining and the identification of acid fast bacilli (AFB) using 
microscopy.  Culture and susceptibility tests are not routinely performed.34  According to the 
World Health Organization’s (WHO) TB treatment guidelines for national programs, a newly 
diagnosed TB patient with positive AFB sputum smears should be started on standard treatment 
with a first-line, four-drug combination regimen (isoniazid, rifampin, pyrazinamide and 
ethambutol).  This regimen should only be changed if the patient remains sputum smear-positive 
for AFB after 3 months of treatment.  At this point evaluation by sputum culture and drug 
susceptibility testing is recommended.34  Laboratory evaluation of sputum with culture and 
subsequent drug susceptibility testing is based on use of solid media.  Although inexpensive, the 
results from this approach confirming MDR TB can take two months or longer.  This approach 
to the diagnosis and management of TB around the world is largely the result of limitations of 
resources and capacity.  Unfortunately, it also leads to extensive delays in the diagnosis of MDR 
TB among patients.  Undetected MDR TB cases can lead to further transmission of the resistant 
strain and to higher mortality, especially in those patients with HIV infection.33 
Over the past few years, however, there has been an increase in the availability of more 
practical and less expensive rapid diagnostic technology.  For example, working in a high MDR 
TB, middle-income Russian community, Balavanova et al. used the Mycobacterium Growth 
Indicator Tube (MGIT) system to significantly reduce the time of diagnosis from months to 
weeks.35  However, this liquid-based system required substantial resources, including various 
supplies and equipment maintenance, making its generalizability to other areas of the world less 
than ideal.   
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Alternatively, fairly rapid and very inexpensive culture-based methodologies, such as the 
microscopic observation drug susceptibility (MODS) assay and the Griess methods are also 
being effectively implemented in resource-constrained settings.   Moore et al. implemented the 
MODS method in an operational setting in Peru.36  This liquid culture method takes 
approximately 7 days to diagnose TB and detects bacterial resistance to all antibiotics at the 
same time.  The sensitivity for detection of TB with this method is 97.8% while the agreement 
between MODS and the reference standard for susceptibility is 100% for rifampin and 97% for 
isoniazid.  Similarly, Asencios et al. implemented a rapid drug susceptibility test (DST) in Lima, 
Peru at a national reference laboratory based on the direct Greiss method.37  This is a 
calorimetric method that uses a nitrate reductase reaction to indicate growth of Mycobacterium 
tuberculosis on a modified Lowenstein-Jensen medium 1 to 3 weeks before colonies become 
visible.  Its implementation in Peru yielded a sensitivity and specificity respectively of 99.1% 
and 100% for isoniazid and 93.5% and 100% for rifampin.  The average time from sputum 
collection to DST result was 31 days, approximately one third of the time required for 
conventional DST.     
Newer and more rapid molecular-based technologies applied directly to sputum samples 
to detect rifampin resistance have been developed over the past decade.  For example, in 2000, 
Traore et al. utilized a line probe assay (LiPA) to detect genetic mutations conferring rifampin 
resistance without requiring culture.  Given that rifampin mono-resistance is highly predictive of 
multidrug resistance, the authors concluded that this method would allow for diagnosis of MDR 
TB within 1 week and often within a few days.38  More recently, the specimen processing 
required by these technologies is being more simplified to allow for easier uptake and 
incorporation into general laboratory use.  All of these tests look for mutations in the core region 
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of the rpoB gene to detect rifampin resistance since numerous studies have shown that this 
region encodes at least 95% of all rifampin-resistant tuberculosis.39  Helb et al., for example, 
described in 2010 an automated molecular test for the presence of Mycobacterium tuberculosis 
(MTB) and resistance to rifampin (RIF).  The Gene Xpert System’s MTB/RIF assay showed 
high sensitivity and produced results in less than two hours with minimal hands-on time.40  
Similarly, Boehme et al. has replicated these results in 1730 patients from four different 
countries and settings including Peru, Azerbaijan, South Africa and India.41  In this study, the 
MTB/RIF assay had a 97.6% sensitivity and 98.1% specificity in identifying resistance to 
rifampin.  Although promising, these rapid susceptibility tests still use sophisticated technology, 
which is costly to manufacture and maintain.  For example, the need for an annual calibration 
was identified as a potential challenge for implementation at peripheral laboratories, especially in 
rural areas of these countries. 
 Management Strategies 
 
 The WHO guidelines serve as a highly useful resource in developing treatment regimens 
for patients with available drug susceptibility and in implementing an empiric treatment for those 
patients that are still waiting for drug susceptibility information.18  These guidelines are the basis 
of treatment for many MDR TB treatment programs globally, including in Peru.  
The guidelines recommend that all newly diagnosed TB patients should have their HIV 
status evaluated.18  HIV prevalence among TB patients has been estimated to be as high as 80 to 
90% in some areas of sub-Saharan Africa.42  In this area of the world, however, HIV testing of 
TB patients varies widely.  Currently, Kenya and Malawi test over 80% of TB patients, but 
estimates are lower in Uganda (60%), Zambia (60%) and South Africa (40%).42  Tuberculosis is 
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often the first clinical indication that a person has underlying HIV infection, and TB services can 
be an extremely important entry point to HIV prevention, care and treatment.  In addition, early 
detection of HIV status of TB patients can make a difference in overall outcome.  Initiation of 
anti-retroviral therapy (ART) for persons with HIV during TB treatment has been shown to 
reduce mortality by approximately 50%.42  However, early initiation of ART (within a few weeks 
of starting TB treatment) means a large number of tablets to ingest, which may discourage 
treatment adherence.  In addition, combination of ART and TB treatment may lead to an increase 
of adverse effects, drug–drug interactions and immune reconstitution inflammatory syndrome 
(IRIS).42 
After HIV testing, quick identification of drug resistance among TB patients should be 
undertaken, especially in areas where HIV is highly prevalent and drug resistance among the 
community’s TB patient is known to be common or increasing.18  The process should start by 
assessing risk factors for MDR TB as previously mentioned, and the use of rapid anti-TB drug 
susceptibility testing, if available, when TB is first diagnosed.  Even if the patient has no risk 
factors for MDR TB at the start of treatment, one should still consider the possibility of 
resistance if a patient’s clinical course is not progressing favorably within a reasonable time 
frame.43 
In general, an individualized approach to treatment, whereby a given patient’s drug 
regimen is tailored to the susceptibility of the cultured strains, is recommended.18  More often 
than not, however, results from susceptibility testing for first and second-line anti-TB 
medications are not available at the beginning of treatment.  Consequently, an empiric approach 
to therapy using a broader range of medications and then tailoring the regimen once results are 
available is followed, especially in resource limited settings.28   
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Previous TB treatment is a strong determinant of drug resistance, and previously treated 
patients comprise a significant proportion (13%) of the global TB notifications in 2007.35  Of all 
the forms of drug resistance, it is most critical to detect multidrug resistance because it makes 
regimens with first-line drugs much less effective and resistance can be further amplified.  At the 
global level, 15% of previously treated patients have MDR, which is five times higher than the 
global average of 3% in new patients.35 
While awaiting the results of conventional drug susceptibility testing, WHO recommends 
administering an empiric re-treatment regimen with first-line drugs for TB patients returning 
after defaulting or relapsing from their first treatment course if country-specific data show low or 
medium levels of MDR in these patients.  The empiric treatment consists of two months of 
Isoniazid, rifampin, pyrazinamide, ethambutol and streptomycin, followed by isoniazid, 
rifampin, pyrazinamide and ethambutol for 1 month.  The regimen then ends with five months of 
Isoniazid, rifampin and ethambutol.35 
If MDR TB is confirmed or suspected, treatment based on DST results or a standard 
MDR treatment regimen should be instituted as soon as possible in order to achieve earlier 
sputum conversion to having no growth of Mycobacterium tuberculosis.  The study by Holtz et 
al. provides an in-depth and well conducted analysis of factors associated with favorable 
treatment outcomes among a cohort of MDR TB patients treated in Latvia.44  This analysis 
actually demonstrates the strong correlation between sputum culture conversion, including when 
it occurs, and final treatment outcomes.  Reducing the time to sputum culture conversion is an 
important infection control measure because patients with MDR TB and positive sputum cultures 
are infectious and may transmit the disease to other persons, family members, and health care 
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providers. This is especially true in settings with limited resources where infection control 
capacity is less adequate.  
Treatment regimens recommended by the WHO for patients who have failed first-line 
treatment or belonging to groups with high likelihood of MDR TB should consist of at least four 
drugs with either certain, or almost certain, effectiveness.  In these cases, effectiveness is 
determined by each country’s drug susceptibility patterns at first.35  As the results to 
susceptibility testing become available, the regimen can be individualized to increase treatment 
effectiveness.  Table 1, adapted from the WHO guidelines for managing MDR TB, categorizes 
all the different anti-TB medications in five groups in order to facilitate the approach to the 
development of a treatment regimen.18  Each group is comprised of at least four medications and 
are grouped based on their relative efficacy.  As the guidelines indicate, optimal treatment is 
based on the use of any remaining first line agents (group 1) to which a given patient’s 
Mycobaterium tuberculosis isolate remains susceptible, followed by the inclusion of an 
injectable agent from group 2 and a fluoroquinolone from group 3.  Agents with bacteriostatic 
activity (group 4) and those medications with only in vitro or anecdotal reports of activity (group 
5) should be added as needed.18 
Due to high number of medications needed to treat MDR TB, patients are often exposed 
to many side effects and toxicities, limiting the actual availability of effective treatment options.  
Thus, identifying and managing these side effects and toxicities as much as possible is often a 
critical aspect of the management of MDR TB in order to reduce the incidence of abandonment 
of therapy and increase cure rates.18, 45 
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 The Impact of Treatment on TB Transmission 
There are few epidemiologic studies that examine the risk to contacts of patients treated 
for variable lengths of time before discharge.  Of these studies, the only randomized controlled 
trial was limited by the high endemic rates of TB in South India in the late 1950s, minimizing the 
difference in exposures between the groups.  These original studies from Madras, India, 
supporting ambulatory care, had shown that compared to treatment in a nosocomial setting, 
treatment at home did no increase the risk of infection or disease for persons living in the 
patient’s home during treatment or over the following 5 years.46,47   
However, the most direct evidence of the impact of treatment on reducing TB 
transmission comes from several animal experiments where large numbers of sentinel guinea 
pigs breathed the air exhausted from experimental TB wards.  The guinea pig (Cavea porcellus), 
a rodent indigenous to the Peruvian Andes, constitutes a well-established animal model to 
quantify TB transmission.  In an experiment conducted by Riley et al. over 60 years ago, all 
transmission to guinea pigs stopped when only sputum smear-positive patients started on 
effective therapy for drug-susceptible TB were admitted to the ward.  Transmission, however, 
resumed when sputum smear-positive drug-resistant patients on ineffective treatment were 
admitted.48  In Riley et al.’s second experiment, the authors demonstrated the rapid effect of 
treatment on reducing transmission.  In this study, sputum smear-positive patients with drug-
susceptible TB just started on treatment were only 2% as infectious as untreated sputum smear-
positive patients.49 
Recently, Escombe et al. repeated those experiments in a similar setting in Peru with HIV 
co-infected TB patients.  This study found that 98% of guinea pig infections were attributable to 
just nine unsuspected or inadequately treated MDR-TB patients among the 97 pulmonary TB 
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patients to which the guinea pigs were exposed.50  Only three patients with drug-susceptible TB, 
all of whom were not on therapy because of delays or side effects, infected a total of three guinea 
pigs.  Globally, delays in the diagnosis of drug resistance mean that many patients may remain 
on ineffective therapy and continue to transmit at rates as high as 20 people per year.8     
The Current Status of TB in Peru 
 
 Peru has suffered from tuberculosis for many years.  In the 1990's, Peruvian and U.S. 
archaeologists discovered mummies in southern Peru more than 1,000 years old, with evidence 
(by PCR) of the presence of pulmonary TB.51  They found tattoos on body sites frequently 
associated with tuberculous cervical lymphadenitis.  Researchers also theorized about the 
possibility that shamans or sorcerers were exploring the use of magical rituals to stop the 
disease.51  Many centuries later and despite the discovery of effective anti-TB medications, 
tuberculosis continues to be a serious national public health threat in Peru.   
Before the DOTS program was launched in Peru in 1990, only 50% of people diagnosed 
with TB were able to get treatment.  Of those, only half were cured.52  During the 1980s, 
inflation in Peru soared uncontrollably and the government was primarily focused in negotiating 
an end to a guerilla war that had left over 70,000 people dead and much of the country’s 
infrastructure, including many of its health centers, destroyed.  Peru suffered from drug 
shortages, including anti-TB medications, a lack of any record system and overworked and 
demoralized public health workers.  This state of affairs in the country was highlighted in 1991, 
when a three-year-old Peruvian boy achieved unwanted celebrity as the last case of polio in the 
entire Western Hemisphere.53  He caught the virus after his local health center was destroyed by 
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Shining Path guerillas, preventing the administration of childhood immunization by local health 
workers. 
During the 1990s, Peru's government recognized for the first time in history that TB 
control was a social, political and economic priority.  This newfound appreciation for the gravity 
of the situation led to the first major increase of the TB budget from US$ 600,000 to US$ 5 
million a year.52  With high-level political commitment, adequate funding for drugs, and 
dynamic leadership, the new DOTS program in Peru had a head start.  Since then, TB diagnosis 
and treatment are provided free of charge, drug financing is sustainable, and the program has 
become a model for training managerial staff from other Latin American countries.54  Drugs, 
equipment and other supplies are purchased and distributed at the central level.  Food packages 
are provided for low-income families as an incentive to comply with treatment and funding has 
been provided to establish patient and family support groups.54  In sparsely populated, remote 
areas such as the Amazon jungle or the high Andean plateau, treatment delivery is adapted to the 
needs of the patient to ensure access and completion of treatment.54  
Over the past two decades, Peru has continued to make considerable progress in the 
prevention and control of TB.  Peru’s national TB program has become one of the world's most 
successful ones, and it has provided some of the first evidence that widespread use of DOTS 
prevents new cases of TB.54  By 1997, the entire population was covered by the DOTS program 
and almost 90% of TB patients were being cured.  A year later, an estimated 94% of TB cases 
were being detected.54  By 1999, the incidence of TB in Peru had decreased almost by half 
through the implementation of DOTS, preventing at least 70,000 to 90,000 deaths.54  In 2004, the 
World Health Assembly, the decision-making body of the WHO, recommended that each 
national TB program achieve a case detection rate of 70% and a cure rate of 85% in order to 
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bring the worldwide TB epidemic under control.55  By 2007, the Peruvian national TB program 
had surpassed both WHO control goals with a detection rate of 90% of all smear-positive cases 
and a cure rate of 92% of all new cases.56  Of all the patients who were treated successfully, 80% 
returned as active members of the Peruvian economy and contributed 174 million nuevos soles 
(US$ 64 million) to the Gross Domestic Product.56  Indeed, the country remains one of only a 
handful of high-burden countries to have met the WHO targets for TB control.56  Over the last 
decade, case notifications for TB have decreased by 32.7%.  Currently, the prevalence of TB in 
Peru stands at 38,000 cases and the incidence of the disease is 125.1 cases per 100,000 
population per year.  By the end of 2011, the national goal is to reduce the number of case 
notifications by another 50%.56  If this trend continues, the incidence of TB in Peru could be 
halved every 10 years. 
Part of the success of TB control in Peru is due to an increase in the number of health 
centers participating in the national TB program.  During the 1990s, the number of health centers 
increased from 1,000 to 6,000 throughout the country.52  In addition, as efforts to detect new 
cases intensified, the number of laboratories capable of carrying out sputum smear tests rose 
from about 300 to over 1000 during the same time period.52  These efforts led to an improvement 
in the diagnostic capabilities of the country as evidenced by the sharp increase in the numbers of 
cases notified between 1990 and 1993.  Since then, the number of new cases has continued to 
steadily declined.52 
The continued success of the national TB program has also paralleled an increase in the 
funding provided by the Peruvian government.  For example, from 1991 to 2005, the average 
yearly budget assigned to medications and laboratory was 3 million dollars.  Since 2006, the 
budget assigned to anti-TB medications and laboratory costs has tripled to an average of US$ 10 
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million per year.  In 2008, the total investment by the government reached a new record of 
approximately 105 million soles (US$ 40 million).52  In order to facility a prompt initiation of 
treatment, the National Institute of Health (INS) has implemented a computerized access system, 
NET Lab, which allows timely access to a patient’s susceptibility testing.  Before 2006, patients 
had to wait approximately 10 months on average to start treatment.  Although this delay is 
currently down to two months, the conditions for delivering effective treatment should continue 
to improve.52  This increase in funding has resulted in the prevention of 256,000 new cases, the 
successful treatment of 64,000 patients and the prevention of 8,000 deaths.52  
Despite these advances in the control of TB in Peru, the country still has one of the 
highest TB incidence rates in the Americas and is among the 22 countries accounting for 80% of 
the new TB cases occurring worldwide each year.  Peru accounts for only 3% of the population 
of the Americas but has approximately 12% of its TB cases.56   In 2007, the regions with the 
highest rates of TB were the Lima Metropolitan area (comprised of Lima city and the port of 
Callao), the southern coastal departments of Ica and Tacna and the Amazonian departments of 
Madre de Dios, Ucayali and Loreto.  Of the 29,393 cases treated for newly diagnosed TB in 
2007, these regions accounted for over 80%.52   
Large cities in developed and developing countries often suffer from higher incidence 
rates of TB, in sectors of poverty and mayor migration.  These figures are always higher than in 
other geographical areas of the country and can even double or triple the overall incidence.  For 
example, Paris suffers from a TB incidence rate four times higher than the national rate while 
Rio de Janeiro and Buenos Aires concentrate 60% and 70%, respectively, of all the MDR TB 
cases in the country.52  Lima is no exception to this global phenomenon where, as a result of the 
social determinants in late 1980s and early 1990's, there was a significant migration towards the 
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capital and other major cities in the coastal region.  With over 9 million inhabitants, the Lima 
Metropolitan area is home to over one third of the country’s population.  Yet, it is responsible for 
58% of all the cases in the country.52  About 86% of all TB cases in the Lima Metropolitan area 
are reported in 18 of its 43 districts, which are characterized by a high degree of overcrowding 
and a rate of disease above the national average. 
 MDR TB in Peru 
 
In 2008, MDR-TB made up 5.3% of all TB cases and 24% of all re-treatment cases in 
Peru.  This constitutes the highest rate of MDR-TB in the Americas.  In addition, more than 200 
cases of XDR-TB were reported.52  Despite these statistics, Peru is the first of the 22 countries 
with a high TB burden to systematically address the problem of resistance to anti-TB antibiotics.  
In fact, the drug resistant TB program in Lima was one of the first to show the effectiveness and 
feasibility of second-line treatment for MDR TB in resource-poor settings, achieving an 83% 
cure rate among patients who completed therapy (73% overall cure rate).57  In order to achieve 
such success, however, the TB program in Lima used an integrated team composed of 
physicians, nurses, health promoters, and DOT volunteers, under intense training, that focused 
not only in the treatment of the disease but also the socioeconomic factors contributing to health 
disparities.  A study by Mitnick et al. demonstrated a cure rate of 63% of XDR TB cases in HIV 
seronegative Lima patients.58  Although  these results represent a breakthrough in MDR and 
XDR TB care, antibiotic costs were $15,681 per patient, a price beyond the reach of most 
national programs.57   
According to Peruvian government figures, from 1997 to 2007, the mortality rate of 
MDR TB in Peru has dropped significantly from 16.2% to 2.2%, below that of TB (2.65%).52   
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This achievement was partly due to the complete reorganization of the laboratory services 
dedicated to the diagnosis of TB made possible by an increase in government funding.  Prior to 
2005, there was only one national reference laboratory in Peru in charge of susceptibility testing 
for multidrug resistant TB (MDR TB).  Susceptibility testing for suspected extreme drug 
resistant TB (XDR TB) was performed in laboratories in the United States.52  There was no 
access to rapid susceptibility testing.  From 2001 to 2004, approximately 13,000 cases of smear-
positive TB cases and 650 MDR TB cases were not diagnosed.52 
Over the past five years, however, the number of conventional susceptibility tests has 
increased by 167% to a record number of 10,275 tests.  This increase in susceptibility testing is 
mainly due to an increase in the number of laboratories performing this test from one to six.  
Four of these laboratories are located in the Lima Metropolitan area.  The other two are located 
in Lambayeque (northern Peru) and Arequipa (southern Peru).  In addition, the INS is able to 
perform susceptibility testing for XDR TB and rapid susceptibility testing, using the Griess 
method, has begun in three districts of health (DISAS) in Lima.  In 2005, the number of reported 
MDR TB cases in Peru reached its peak at 2,436.  The following year, the number of cases 
dropped to 1,825 cases and then to 1,785 cases in 2007.  This number of MDR TB cases 
nationwide has decreased despite an increase of the capacity for detecting multidrug resistance, 
as explained above.   
The Lima Metropolitan area is responsible for approximately 82% of MDR TB cases and 
93% of XDR TB cases in Peru.52   In particular, thirteen districts (San Juan Lurigancho, San 
Martin de Porres, La Victoria, Ate, Lima Cercado, San Juan de Miraflores, Comas, El Agustino, 
Santa Anita, Villa Maria del Triunfo, Villa El Salvador, Independencia and Los Olivos) report a 
higher rate of MDR TB than the rest of the Lima Metropolitan area.  Also, of the 186 confirmed 
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XDR TB cases in the entire country,158 (85%) of them are concentrated in the districts of La 
Victoria, Lima Cercado, San Martin de Porres, San Juan de Lurigancho, Ate, Santa Anita and El 
Agustino.52 
Correlation of Cough Frequency with Treatment Efficacy in Pulmonary TB patients in 
Lima, Peru: A prospective study 
 
The remainder of this thesis presents an original research study conducted by the 
author in a low-income, urban setting in Lima, Peru. 
 
Introduction 
 
Current World Health Organization guidelines recommend sputum-smear examination at 
the end of the second month of treatment in patients with recently diagnosed pulmonary TB.34  If 
positive, a repeat examination is recommended at the end of the third month.34  If the specimen 
obtained at the end of month 3 is still smear-positive, sputum culture and drug susceptibility 
testing are then recommended.34  Treatment failure is defined as smear or culture positivity at the 
fifth month or later.34  Many countries, including Peru, follow these recommendations and repeat 
sputum microscopy test on a monthly basis during the course of anti-TB therapy to assess the 
response to treatment.60   
In 2000, Becerra et al. reported that treatment failure while on DOTS in Lima, Peru was 
strongly correlated with active MDR-TB.  Of 173 cases of treatment failure identified, 150 
(86.7%) had active, pulmonary MDR-TB.61  Furthermore, the authors concluded that short-
course chemotherapy for these patients would only serve to amplify ominous existing drug 
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resistance patterns. 61  During the same year, Chavez Pachas et al. performed a case control study 
in order to identify risk factors for treatment failure while on DOTS.62  In this case, all 38 cases 
were smear-positive at 2 months of therapy, which was strongly associated with failure (OR 
11.7; CI 2.4-57.5).62  Of these patients nearly 75% had MDR-TB.62   
Although Chavez Pachas et al. reported that positive sputum microscopy at second month 
of treatment is associated with subsequent treatment failure, this indicator of treatment outcome 
has proven insensitive at the population level.  A recent systematic review and meta-analysis by 
Horne et al. revealed that 2 month-smear had low sensitivity (57%, CI 41-73%, seven studies) 
and higher, although modest, specificity (81%, CI72-87%; seven studies) when predicting 
treatment failure.63  In other words, a positive sputum result during treatment did not imply that 
an individual will experience a poor outcome from TB.  However, a negative sputum result did 
imply that an individual will be unlikely to experience treatment failure.63  Thus, the widespread 
use of this test and its uncertain utility suggest a critical need to appraise tests and strategies 
suitable for resource-limited settings used to identify patients at risk for poor outcome before the 
three month marker recommended by the WHO.      
The Case for Cough Frequency 
Coughing has long been identified as an important determinant of infectiousness in TB. 
Cough-inducing procedures, for example, have been associated with extensive transmission of 
the disease.  In 1982, Catazaro documented a high rate of tuberculin skin test conversion in 
hospital staff exposed to a smear-negative, culture-positive patient in a respiratory intensive care 
unit.64  During his stay at the hospital, this patient required bronchoscopy, intubation and assisted 
ventilation.  Of the hospital staff members who were exposed to the index case, 14 of 45 (31%) 
converted their tuberculin skin test.64  Ten of 13 (77%) hospital staff members present at the time 
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of bronchoscopy converted, compared with 4 of 32 (12.5%) who were not present at 
bronchoscopy (Fischer's exact test p = 0.0006).64   
  In 1990, Malasky et al. examined the risk of conversion to a positive tuberculin skin test 
associated with certain medical procedures involving the lower respiratory tract.65  The study 
looked at Pulmonary fellows from 14 different training programs who routinely performed 
procedures identified as important sources of respiratory aerosols, which have the potential for 
the transmission of TB.  These procedures included fiberoptic bronchoscopies, endotracheal 
intubations and mechanical ventilation.  Over a period of three years, seven of 62 (11%) 
Pulmonary fellows at risk converted their tuberculin skin test as opposed to one of 42 (2.4%) 
Infectious Disease fellows who served as controls.65 
A case control study by Calder et al exploring the association between the production of 
respiratory aerosols and risk of infection took place at a Florida health clinic.  Between January 1 
and June 30, 1988, 30 of 76 (39.5%) staff members tested at this clinic had positive tuberculin 
skin test reactions.66  The staff members whose skin test converted were more likely than those 
whose skin test did not convert to have been present while patients were being treated with 
aerosolized pentamidine (odds ratio = 15.0; 95%; CI = 1.4 - 730.0) and to have worked on the 
first floor of the clinic (odds ratio = 9.3; 95% CI = 1.1 - 420).61  The clinic building was poorly 
ventilated, and aerosolized pentamidine treatments were given in a room from which the air 
tended to flow into the hallway.66   
In 1969, Loudon et al. conducted a study in Dallas, TX with 63 newly diagnosed 
pulmonary tuberculosis patients.  This was the first and only paper that looked specifically at 
cough frequency as an index of infectivity and to measure changes in cough frequency in TB 
patients during treatment with anti-TB antibiotics.67   Although cough frequency at the time of 
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admission did not prove to be a satisfactory index of infectivity, the decline in cough frequency 
during treatment with anti-TB drugs was rapid.67  Most patients reduced their cough count to half 
the initial value within two weeks.67  Thus, patient’s cough frequency might be a helpful and 
inexpensive marker to predict TB treatment outcome. 
Research Setting 
 
Peru is a South American country with a population of approximately 29.2 million 
people.68  It is a relatively poor country with a gross domestic product per capita of $8,120.68  
The life expectancy of the population ranges from 74 years in males to 77 years in females, while 
the adult mortality rate (per 1000 adults 15-59 years) is 110 for both sexes.68  The country has a 
low prevalence of HIV of 4 (per 1000 adults 15-59 years) and, as stated before, a TB prevalence 
of 129 per 100,000.68 
Approximately, 72% of the population of Peru lives in urban areas.68  Lima, the capital 
city, is home to approximately 8 million Peruvians or one third of the country’s population.69  
The incredible growth of Lima over the past five decades is the result of many factors that have 
pushed people out of their rural communities: the loss or lack of adequate farmland, natural 
disasters such as earthquakes and landslides, lack of employment options, and a host of personal 
reasons.  In addition, since the outbreak of terrorist activities by the Shining Path movement in 
1980 and subsequent military reactions, over a million people were displaced from towns and 
villages in the Ayacucho and Huancavelica highlands, most of them gravitating towards Lima.70 
The process of urban growth in Lima has produced an urban configuration that conforms 
to no central plan. Without access to adequate housing of any type, and without funds or 
available loans, migrants set about developing their own solutions by establishing organizations 
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of their own.  They planned a takeover of unoccupied land at the fringes of the city and, with the 
suddenness and effectiveness of a military operation, invaded the property.  Once on the land, the 
migrants laid out plots with precision and raised temporary housing in a matter of hours.  Called 
pueblos jovenes (“young villages”), the shantytowns quickly developed both an infrastructural 
and a sociopolitical permanence.  By early 1990, approximately half of Lima’s population lived 
in these conditions.70  The disorganized expansion of Lima led to a large sector of this population 
without basic services, including clean water, electricity, proper sanitation and access to health 
care.  These conditions resulted in hyperendemic clusters of TB where the annual incidence of 
the disease reached four times the city’s average incidence.71        
 The Hospital Nacional Dos de Mayo, centrally located in Lima’s historic center 
(Downtown district), is a 850-bed teaching hospital that is run by the Peruvian Ministry of 
Health (MINSA healthcare system).  As with other MINSA institutions, this hospital provides 
services to the Peruvian poor and uninsured since its establishment in 1875.  The Infectious and 
Tropical Diseases Service at the Hospital Nacional Dos de Mayo is the major referral center for 
HIV and TB patients in Lima and is the only hospital in Peru with two 4-bed, negative-pressure 
rooms available for TB patients.72 
Aim  
 
The specific aim of the study is to assess the change of pulmonary TB patients’ cough 
frequency over time depending on TB treatment outcome. The broader aim of this study is to 
develop a helpful and cheap marker to predict TB treatment outcome.  Ultimately, this 
information will enable physicians to make better decisions with regard to transmission risk of 
pulmonary TB patients undergoing treatment in resource-limited settings.  
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Hypotheses 
 
1. In patients undergoing treatment for pulmonary tuberculosis, cough frequency diminution will 
occur significantly earlier in patients with susceptible TB strains versus those with resistant strains.  
2. Cough frequency diminution will be an independent predictor of TB susceptibility.   
Methods 
 
Description of study population 
The study population was derived from patients under the care of the Infectious and 
Tropical Diseases Service of the Hospital Nacional Dos de Mayo and their referral centers, on 
both inpatient and outpatient services.   Patients with TB suspected either clinically or 
radiologically were recruited for the study.  The study team physician, student investigator, or 
nurse communicated daily with the medical staff and reviewed the patient logs to identify all 
possible study patients who fit the inclusion criteria.  All possible study patients were recruited 
during the study period as space and equipment permitted.   
Patient identifiers including name, address and other contact information such as email or 
phone numbers were collected by the nurses in order to facilitate the coordination of follow-up 
visits.   This information, however, was never available to the study team and was not used in the 
actual study.   
Data collection 
The study team interviewed those prospective subjects willing to enroll in the study.  
Once these patients agreed to enter the study, the study team doctor or student investigator 
completed a form including clinical data and demographic information.   During the interview 
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the purpose of the study as well as its risks and benefits was explained to the patient.  The study 
team physician or student investigator gave the informed consent form to the patient so that the 
patient could read it and sign it if they agreed to enter the study.   If the patient (or his or her 
representative) chose to sign the informed consent, the study team proceeded to complete the 
patient’s study record with information provided by the patient.  Demographic information as 
well as risk factors or current treatment for TB was collected (known contacts, previous 
diagnosis of TB, INH prophylaxis, etc.).  Patient’s HIV status was also reviewed, and 
information on CD4 count and viral load, if available, was collected.   Subjects underwent 
screening for active TB by sputum smear and MODS culture.  Additionally, female subjects 
underwent pregnancy testing by qualitative urine β-HCG. 
 Inclusion criteria:   
-  18 years of age or older. 
- Active pulmonary tuberculosis diagnosed by positive sputum smear and/or sputum 
culture. 
Exclusion criteria: 
 - Pregnant at time of subject screening. 
- Unwilling or unable to provide informed consent. 
- Presence of extra-pulmonary tuberculosis  
The physician, student investigator and/or nurses in charge of the study explained this 
study design to all potential participants.  Any points that were not completely understood were 
explained in detail.  In the case of illiterate patients, the consent form was read out loud in its 
entirety.  Consent was documented by the signature of the patient and by the signature of a 
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witness if present.  If illiterate, consent was documented by the patient’s fingerprint and by the 
signature of a witness. Papers used for data collection were locked in a secured locker.   
 The study is a prospective cohort study.  Patients who fit the inclusion criteria as described 
above were approached and asked whether they would like to learn about the study.  If patients 
chose to provide their informed consent, they underwent a chest x-ray (CXR), a review of the 
history and a physical exam.  Once these exams were completed, patients were hospitalized in 
the Hospital Nacional Dos de Mayo for a period of between 9 and 16 days (days -1 to 14, 
inclusive).  Day 0 is defined as the day that a new anti-TB regimen was started, whether primary 
treatment or retreatment in cases of MDR-TB.  However, treatment was not delayed if the patient 
was too ill, as assessed by ward staff.    
The main outcome of the study was cough frequency, recorded in the questionnaire as 
coughs per day on days -1 (baseline), 0 (start of treatment), 3, 7, 14, 21, 30, and 60 (each +/- 2 
days).  During the study the following data were collected: patient weight, temperature, self-
reported cough frequency and self-reported medication compliance. At day 14, patients were 
discharged if appropriate for their clinical condition as determined by medical ward staff, and 
subsequently followed as outpatients.  If the patients’ health permitted, and they so desired, they 
were sometimes discharged as early as day 7 and subsequently followed as outpatients.  When 
patients returned for outpatient appointments, the same information was obtained.  The study 
terminated at day 60. 
The Peruvian national guidelines for the control and prevention of TB defines treatment 
failure based on positive sputum microscopy results after ≥ 5 months of treatment or reverting to 
positive after two consecutive negative monthly results.60  Since the study only followed patients 
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for a maximum of 60 days, treatment failure in this study was defined as the detection of 
resistance by sputum culture or death which was defined as those patients who died during 
tuberculosis therapy follow-up.  For the data analysis, the patients were dichotomized by those 
having a good outcome and those having an adverse or poor outcome (death or treatment failure, 
as previously defined). 
Other variables of interest included in the analysis were: age measured in years, patient 
sex (male or female), treatment scheme (new vs. recurrent), change of sputum during treatment 
assessed monthly, and HIV status. 
Risks to Human Subjects 
 
The study design was reviewed and approved by the Institutional Review boards of Asociacion 
Benéfica PRISMA (Lima, Peru), Hospital Nacional Dos de Mayo (Lima, Peru) and the University of 
Connecticut Health Center (Farmington, CT).Patients diagnosed with active TB were enrolled in the 
national TB control program as per the usual protocol.  During the course of the study all clinical 
decisions and patient care were the responsibility of the medical ward staff.  The study team did 
not interfere with ward treatment plans and provided all results of patient discussion, labs, and 
microbiology to the medical ward staff in a timely and appropriate manner.  In addition relevant 
results were provided to subjects in a timely manner.  
Statistical Analysis 
 
Sample size calculations were performed using a T test, and setting a two-sided alpha to 
.05 and the power to 80% to compare subjects no longer coughing to subjects still coughing.  
Using a 20% difference in results such that, for example, 80% of those no longer coughing have 
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negative microbiology compared to 60% of those still coughing, a sample size of 164 is 
calculated.  Assuming a drop-out rate of 30%, we need 234 patients to find the above difference 
in effect size.  Therefore, the final sample size is estimated to be about 250 patients.   
 Data were entered first into Excel and then analyzed using STATA version 11.0 for 
Windows.  First a brief description of demographic and clinical characteristics was tabulated.  
Second, cough frequency was calculated for each group according to our outcome of interest and 
day of follow-up.  Finally, a longitudinal analysis was carried out to evaluate cough frequency 
over time.  A marginal model was fitted using Generalized Estimating Equations to model 
average cough frequency trends for patients with good and poor outcomes.  The crude model was 
determined as follows:  
Yij = B0 + B1.Outcome + B2.Tij + B3.Tij.Outcome 
Where Yij  is the mean cough frequency (number of coughs per 24 hour period) in patient “i” at 
time “j”; B0 is the intercept, i.e. cough frequency in number of coughs per 24 hour period among 
those with good outcome at baseline; B1 is the difference in cough frequency in patients with 
poor outcome compared to those with good outcome at baseline; and B2 quantifies the change in 
cough frequency between baseline and one selected follow up visit for participants with good 
outcome.  The sum of B2 and B3 (interaction term) represents the change in cough frequency 
between baseline and one selected follow up for participants with poor outcome.  In this model, 
the time variable, Tij, was included as categorical because weight over time did not show 
linearity in the poor outcome group. 
 Quasi-likelihood under the independence model information criterion (QIC), an extension 
of the Akaike’s information criterion (AIC), was applied to find the best working correlation 
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structure applicable for the proposed model.  The Akaike’s information criterion is a measure of 
the relative goodness of fit of a statistical model.   It is grounded in the concept of information 
entropy, in effect offering a relative measure of the information lost when a given model is used 
to describe reality.  It can be said to describe the tradeoff between bias and variance in model 
construction, or loosely speaking between accuracy and complexity of the model.  Given a data 
set, several candidate models may be ranked according to their AIC values.  From the AIC 
values one may also infer that, for example, the top two models are roughly in a tie and the rest 
are far worse. Thus, AIC provides a means for comparison among models, a tool for model 
selection. 
Additionally, the model was adjusted for potential confounders affecting both outcome 
and cough frequency.  Potential confounders included were age, sex, HIV status, and sputum 
microscopy result change during treatment.  Wald test was used to report p-values, whereas 
robust standard errors were used to calculate 95% confidence intervals for each coefficient in the 
model.   
Results      
 
 A total of 250 patients started anti-TB treatment during the period of study and were 
eligible for this study.  However, 45 patients did not have TB, 6 had started treatment before the 
start of the study, 4 had other co-morbidities that did not allow them to participate, 3 abandoned 
therapy, 2 moved away before starting treatment, 2 developed altered mental status due to HIV 
encephalitis and 2 had extra-pulmonary TB.  Therefore, only 141 (56.4%) patients were included 
in the analysis; 71.6% of them were males and the mean age was 30.5 years (SD: 14.1; range: 
18-78).   
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Of the total number of patients, 13 (9.2%) had a poor outcome at the end of the study 
period (11 had failed and 2 died).  When compared to the patient group that had a good outcome, 
the poor outcome group was older, with a mean age of 38.4 versus a mean age of 30.8 years 
(p<0.001).  In addition, this group had an average household income of 307 nuevos soles ($ 
110.00) per month, which is significantly lower than the good outcome group’s average 
household income of 652 nuevos soles ($ 233.00) (p < 0.04).  In addition, all 13 patients in the 
bad outcomes group came from only three Lima districts: Carabayllo (6), Cercado de Lima (4) 
and San Juan de Miraflores (3).   On the other hand, 13 different districts were represented in the 
good outcome group.  A brief description of patients’ characteristics in relation to outcome status 
is shown in Table 2.  
 Table 3 shows a detailed description of cough frequency variation during treatment 
follow-up without accounting for intra-subject correlation.  Each cough count represents the 
mean number of coughs per day that the patients reported during treatment.  There was no 
significant difference between cough frequency of the outcome groups at baseline (p = 0.12).  
However, on average, during the first two weeks cough frequency did not decrease in those who 
developed an adverse outcome whereas it declined among those who had a good outcome. 
Results of crude and adjusted marginal models are shown in Table 4. Of interest, the 
adjusted coefficient for adverse outcome was not significant (p = 0.17), indicating that the 
difference in cough frequency (approximately 10 coughs per 24 hr period) among patients with 
poor and good outcome at baseline was not statistically different.  However, the interaction terms 
together were significant (Wald test for interaction, p = 0.002) indicating that changes of cough 
frequency over time among patients with poor outcome differed from those with good outcome 
(Figure 1). Based on the results of the adjusted model (Table 4), at the end of the first two weeks, 
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on average, the cough frequency in patients with good outcome decreased by approximately half 
(-62.82 cough per 24 hour period according to the adjusted model) compared to baseline; at the 
end of the first month, cough frequency decreased by approximately 81 coughs per 24 hour 
period in this group of patients.  On the other hand, the cough frequency in patients with poor 
outcome remained constant at approximately 110 coughs per 24 hour period after the first two 
weeks of therapy compared to the baseline, while decreasing by approximately 15 coughs per 24 
hour period after the first month of treatment.   
 Discussion 
 
 This study shows that, after adjusting for potential confounders, the curve of cough 
frequency over time among patients who developed adverse outcomes is completely different 
from patients classified in the good outcome group at the end of the study (Figure 1).  The 
association continues being statistically significant after having included the monthly sputum 
microscopy result as confounder, pointing out that change in cough frequency over time is an 
independent predictor of treatment outcome. 
These findings might have an important impact on public health, especially in resource-
limited settings. Cough frequency assessment might be an easy, cheap, and useful way to predict 
anti-TB treatment outcome among pulmonary TB patients receiving therapy.  Constant or 
increased cough frequency after the end of the first two weeks of therapy might be an important 
indicator that further attention is needed to help avoid deaths or failures.  Remarkably, most of 
the divergence of cough frequency over time occurred during the first two weeks of anti-TB 
therapy.  After that, cough frequency among poor outcome patients shows parallel trends 
compared to good outcome ones with, however, a slightly lower rate.   
40 
 
These findings suggest that we can apply strategies as soon as the end of the first two 
weeks to avoid deaths and failures, including MDR testing and closer monitoring. A total of 10 
out of 13 patients who failed treatment in this study were diagnosed as MDR-TB cases after 
failing; two had TB strains resistant to isoniazid and one had a TB strain resistant to rifampin 
(data not shown). 
The TB burden follows a strong socio-economic gradient between countries, within 
countries, and within communities, and the poorest have the highest risk.  In India, a community 
survey found that the prevalence of TB was higher amongst the landless, those living below the 
poverty line and in katcha houses (houses constructed from mud, stone and wooden beams), 
suggesting that TB disproportionately affects those with a low standard of living index (SLI).73  
In this study, all 13 cases who failed came from districts located in the outskirts of Lima.  These 
areas of the city have suffered from patterns of social and economic development that include 
rapid urbanization, inequitable economic growth and presence of large pockets of social 
deprivation, all of which are associated with TB. Studies assessing the burden of TB in specific 
vulnerable populations such as prisoners, the homeless, and certain ethnic minorities also show 
that there is a strong association between social deprivation and TB risk.74,75  However, the causal 
pathways linking poverty and low socio-economic status to increased risk of TB are not fully 
understood. 
Strengths of this study include the use of longitudinal, prospective data to assess cough 
frequency change among pulmonary TB patients commencing treatment.  Another important 
strength is the use of longitudinal analysis with the best working correlation structure taking into 
account several potential confounders including changes on sputum microscopy results during 
follow-up, one of the best-known predictors of TB treatment outcome. 
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However, this study also has some limitations. Although all possible patients who fit the 
inclusion criteria were included in the study, only a small number of failures occurred during the 
period of the study.  As a result of the low number of cases in the study, potential treatment 
outcomes were joined during analysis which might lead to misclassification.  In addition, the 
small number of cases makes it difficult to generalize the result to other areas of the world, 
where the rate of MDR TB might be lower.  Furthermore, the group of patients who participated 
in this study had a combined HIV prevalence of approximately 32%.  This rate is considerably 
higher than the national Peruvian prevalence of approximately 1.5%.52  As stated before, most of 
the patients who entered the study came from the Hospital Nacional Dos de Mayo, which acts as 
a referral center for the city of Lima for complicated TB cases.  Consequently, the results of this 
study might be difficult to generalize to areas of Peru and the world where the prevalence of TB 
and HIV co-infection is not as high.   Nevertheless, the findings agreed with the previous report 
by Loudon showing the association between cough frequency reduction and anti-TB treatment in 
Texas.67   
Due to the small sample number, other co-morbidities which can present or include 
cough in their symptomatology could not be excluded.  These can include chronic diseases that 
can affect the lungs such as cancer or emphysema.  However, patients can also suffer from acute 
diseases such as viral upper respiratory infections, allergies or acid reflux.    
Finally, the determination of cough frequency was done through the administration of a 
questionnaire.  As with all studies based on this data-gathering method, it was subject to recall 
bias by the patients.  Although the questionnaire asked the patients to recall the last 24 hours 
before every visit, it is possible that those patients who were sicker or had a higher rate of 
coughing remembered more accurately than those who had a lower or decreasing cough 
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frequency.  Another important bias associated with the administration of the questionnaire is the 
response bias.  Before participating in the study, each patient was informed about the goals of the 
study during the informed consent sessions.  Consequently, having this information, some of the 
respondents might have answered questions regarding cough frequency in a way they thought 
might please the administrators of the questionnaire.     
 Conclusions and Recommendations 
In summary, the findings of this study reveal that trends and change of cough frequency 
during anti-TB therapy can predict treatment outcome.  Thus, cough frequency during the first 
two weeks of therapy should be used as part of the routine clinical evaluation.  Patients with 
unchanged or increased cough frequencies after two weeks of treatment should be more closely 
followed as they are at risk of adverse outcomes.  Follow-up monitoring might include MDR 
diagnosis testing, closer monitoring or determination of HIV infection status or treatment of 
opportunistic infections.   
Although it would be ideal to use an ambulatory cough meter as an objective method to 
assess the cough frequency of pulmonary TB patients, this is currently not yet practical.  Once 
this ideal situation arises, further studies are needed to find appropriate cough frequency cutoffs 
including sensitivity and specificity analysis and assess the combination of sputum microscopy 
results with cough frequency over time to predict TB treatment outcomes. 
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Tables and Figures 
Table 1: Group of Drugs to Treat MDR TB*18  
Group 1 Available first-line agents: pyrazinamide, 
ethambutol  
The most potent and best tolerated.  They 
should be used if there is good laboratory 
evidence and clinical history to suggest that a 
drug from this group is effective. 
Group 2 At least one injectable agent: kanamycin, 
amikacin, capreomycin, streptomycin 
All patients should receive a Group 2 
injectable agent if susceptibility is 
documented or suspected. Kanamycin or 
amikacin is generally the first choice, given 
the high rates of streptomycin resistance in 
this population. 
Group 3 At least one fluoroquinolone: 
levofloxacin, moxifloxacin, ofloxacin 
A fluoroquinolone should be added based on 
DST* and treatment history. When resistance 
to ofloxacin or XDR TB* is suspected, a 
higher-generation fluoroquinolone should be 
used. 
Group 4 One or more second-line oral 
bacteriostatic agents: para-amino-
salicylic acid cycloserine, terizadone, 
ethionamide or protionamide 
Group 4 drugs are added until the patient is 
receiving at least four drugs likely to be 
effective.  The best choice is based on 
treatment history, adverse-effect profile, and 
cost. 
 
DST* is not standardized for drugs in this 
group. 
Group 5 Drugs of unclear role in MDR TB*: 
clofazimine, linezolid 
amoxicillin/clavulanate, thiacetazone, 
imipenem/cilastatin, 
high-dose isoniazid, clarithromycin 
The efficacy of Group 5 drugs in multidrug 
regimens is unclear and should only be 
considered if there are not four drugs likely 
to be effective from Groups 1–4. 
Consultation with MDR TB* expert should 
be considered. If drugs are needed from 
Group 5, it is recommended to add at least 
two. 
 
DST* is not standardized for the drugs in this 
group. 
*DST drug-sensitivity testing, MDR TB multidrug-resistant tuberculosis, XDR TB extensively drug-resistant 
 
44 
 
Table 2: Characteristics of enrolled patients at baseline according to outcome status 
Variable Good Outcome (n=128) Poor Outcome (n=13) p-value 
Sex 
Female 36 (28.1%) 4 (30.8%) 0.82 
Male 92 (71.8%) 9 (69.2%)  
Age (years) 
Mean (SD) 30.8 ( 13.2) 38.4 (19.4 ) <0.001 
Sputum result 
Negative 37 (28.9%) 3 (23.1%) 0.64 
1+ 49 (38.3%) 5 (38.5%)  
2+ 23 (18.0%) 3 (23.1%)  
3+ 19 (14.8%) 2 (15.4%)  
HIV infection 
Negative 86 (67.2%) 10 (76.9%) 0.002 
Positive 42 (32.8%) 3 (23.1%)  
Monthly household income (nuevos soles) 
Mean (SD) 652 (140) 307 (73.6) 0.04 
Residence by district 
District (N) Lima Cercado (32) 
San Juan de Lurigancho 
(25)  
Comas (14) 
La Victoria (11) 
El Agustino (10) 
Ate (10) 
Others (26) 
 
Carabayllo (6) 
Lima Cercado (4) 
San Juan de Miraflores (3) 
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Table 3: Cough frequency change over time during follow-up according to outcome status. 
Cough 
frequency 
(coughs per 
hour ) 
Treatment outcome 
 Good outcome Poor outcome 
 N Mean (SD) N Mean (SD) 
Day -1 
(Baseline)  
128 129.9 (9.2) 13 119.3 (8.7) 
Day 0 (Start of 
Treatment) 
128 125.4 (9.3) 13 118.0 (8,8) 
Day 3 127 104.0 (9.2) 13 120.5 (8.5) 
Day 7 120 80.3 (9.7) 12 119.3 (8.9) 
Day 14 119 65.9 (9.8) 10 121.8 (9.0) 
Day 21 118 60.2 (8.4) 10 115.1 (9.3) 
Day 30 109 54.3 (8.9) 7 103.6 (9.2) 
Day 60 64 20.7 (9.9) 3 46.0 (5.9) 
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*Adjusted by age, gender, HIV status and sputum microscopy 
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Figure 1: Cough frequency change over time during treatment follow-up 
according to outcome (*adjusted model).
Good Outcome Poor Outcome
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Table 4: Crude and adjusted marginal models assessing cough frequency change over time 
according to outcome status 
 Crude model Adjusted model* 
 B 95% CI p-value B 95% CI p-value 
Intercept 129.90 122.7;137.1 <0.01 121.43 114.45;128.41 <0.01 
Poor 
outcome 
-10.60 -18.40;-2.81 0.145 -8.45 -15.55;-1.35 0.193 
Day 0 
(Start of 
Treatment) 
-4.45 -4.67;-4.23 <0.01 -4.63 -6.41;-2.85 <0.01 
Day 3 -24.72 -27.01;-22.43 <0.01 -25.45 -29.45;-21.45 <0.01 
Day 7 -48.95 -50.05;-47.86 <0.01 -45.89 -49.57;-42.21 <0.01 
Day 14 -63.70 -68.93;-58.47 <0.01 -62.82 -68.90;-56.74 <0.01 
Day 21 -69.54 -74.73;-64.35 <0.01 -71.02 -74.78;-67.26 <0.01 
Day 30 - 75.59 -79.52;-71.66 <0.01 -76.36 -81.05;-71.67 <0.01 
Day 60 -109.32 -116.52;-
102.12 
<0.01 -107.74 -114.45;-
101.03 
<0.01 
Poor 
Outcome* 
Day 0 
(Start of 
Treatment) 
-11.72 -15.5;-7.99 <0.01 -10.94 -14.84;-7.04 <0.01 
Poor 
Outcome* 
Day 3 
-10.55 -16.65;-4.45 0.01 -11.06 -16.81;-5.31 0.02 
Poor 
Outcome* 
Day 7 
-11.86 -15.76;-7.96 0.02 -11.45 -16.07;-6.83 0.03 
Poor 
Outcome* 
Day 14 
-10.54 -15.56;-5.52 0.017 -10.67 -17.73;-3.61 0.02 
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Poor 
Outcome* 
Day 21 
-14.89 -17.87;-11.91 0.012 -15.63 -18.57;-12.69 0.018 
Poor 
Outcome* 
Day 30 
-23.56 -29.80;-17.32 0.02 -25.00 -33.36;-16.64 0.017 
Poor 
Outcome* 
Day 60 
-84.78 -91.77;-77.80 0.025 -82.99 -89.27;-76.71 0.33 
*Adjusted by age, gender, HIV status and sputum microcopy 
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